Isaac Ciechanover, M.D.
CEO & President
Dr. Isaac Ciechanover is a physician, investor and entrepreneur driven by a passion to improve the practice of medicine. Motivated by the belief that the majority of medical discoveries still lie ahead, he has dedicated the past 20 years to working with entrepreneurs and life sciences organizations to advance medicine through innovation and technology. He founded Atara Biotherapeutics in August 2012. Previously, he was a partner in the life sciences practice at Kleiner Perkins Caufield & Byers. Earlier as Celgene’s Executive Director for Business Development, he spearheaded the company’s venture capital efforts and led licensing and M&A activities with an aggregate value of more than $6.7 billion. Also at Celgene, he was Global Project Leader for the company’s first clinical-stage biologic therapy. Isaac has also held business development and venture capital roles at Amylin Pharmaceuticals, Pequot Ventures’ healthcare practice and Pfizer. Intellectually curious (and undeterred by student debt), Isaac holds a B.A. from Stanford University, an M.Phil. in Epidemiology from Cambridge University, an M.D. from Weill Cornell Medical College and an M.B.A. from Harvard Business School. For fun, he enjoys cycling, scuba diving and building Lego with his two children. His all-time favorite albums are Pink Floyd’s “The Dark Side of the Moon,” Radiohead’s “OK Computer” and Ruggero Leoncavallo’s Italian opera, Pagliacci, with Herbet Von Karajan conducting.
Roy D. Baynes, M.D., Ph.D.
Roy Baynes is Senior Vice President Global Clinical Development and Chief Medical Officer at Merck Research Laboratories in Rahway, New Jersey. He was previously Senior Vice President of Oncology, Inflammation and Respiratory Therapeutics at Gilead Sciences and prior to that was Vice President Global Clinical Development and Therapeutic Area (TA) Head for Hematology / Oncology, at Amgen Inc. He graduated as a Medical Doctor and obtained a Master of Medicine and Doctor of Philosophy from the University of the Witwatersrand, Johannesburg, South Africa. He has had a long and distinguished career in the haematology-oncology-and stem cell transplantation fields, including drug development, basic research, clinical practice, clinical research, teaching and administration. He is a member of many international societies, including the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO), and has authored some 150 publications. He has been recurrently named among America’s top physicians. Before joining Amgen in 2002, he was the Charles Martin Professor of Cancer Research at the Barbara Ann Karmanos Cancer Institute, an NCI designated Comprehensive Cancer Center, at Wayne State University, Detroit, Michigan, USA.
Eric Dobmeier is an experienced biotechnology executive with more than 15 years of industry experience. He most recently served as President and Chief Executive Officer of Silverback Therapeutics, a private Seattle-based biotechnology company. Previously, he was Chief Operating Officer of Seattle Genetics, overseeing business development, corporate communications, manufacturing and program/alliance management activities, as well as corporate strategy initiatives. While at Seattle Genetics, Eric was directly involved in raising more than $1.2 billion in equity capital, and led negotiation and completion of multiple corporate alliances with leading biotechnology and pharmaceutical companies. Prior to that, he was with the law firms of Venture Law Group and Heller Ehrman LLP where he represented technology companies in connection with public and private financings, mergers and acquisitions and corporate partnering transactions. Eric received a J.D. from University of California, Berkeley School of Law and an undergraduate degree from Princeton University. He is also a director of Adaptive Biotechnologies and Versartis.
Director, Audit Committee Chair
Matthew Fust is an advisor to life sciences companies. He was Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals from January 2009 through its acquisition in October 2013. From May 2003 to December 2008, Matthew served as Chief Financial Officer of Jazz Pharmaceuticals. From 2002 to 2003, he served as Chief Financial Officer of Perlegen Sciences. Previously, he was Senior Vice President and Chief Financial Officer of ALZA Corporation, where he was an executive from 1996 until 2002. From 1991 until 1996, Matthew was a member of Andersen Consulting’s healthcare strategy practice. He received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.
Matthew is a director of Dermira, MacroGenics, and Ultragenyx Pharmaceutical.
Carol G Gallagher, Pharm.D.
Dr. Carol Gallagher serves as the Lead Independent Director of Atara Biotherapeutics. She recently joined the life sciences practice of New Enterprise Associates as a Partner. She serves as Chairman of AnaptysBio and as a Director at Millendo Therapeutics.
From 2008-2011, Carol was the president and CEO of Calistoga Pharmaceuticals that developed the first-in-class cancer therapeutic, CAL-101, now known as ZYDELIG. During her tenure as CEO at Calistoga Pharmaceuticals, Carol raised $80 million in venture financing and led the company to a successful exit with the acquisition by Gilead Sciences in April 2011 for $375 million and a total consideration of $600 million. Gilead continued to rapidly advance registration trials of ZYDELIG in patients with certain types of leukemia and lymphoma. In 2014, ZYDELIG was approved in the US and Europe for three indications simultaneously.
Carol studied chemistry at Vanderbilt University and then pursued a clinical background, attaining Bachelor of Science and Doctor of Pharmacy degrees from the College of Pharmacy at the University of Kentucky.
Mr. Heiden is an experienced pharmaceutical and biotechnology executive. He joined AMAG Pharmaceuticals, Inc. (AMAG) in May 2012 as president and chief executive officer. Mr. Heiden is also a member of AMAG’s board of directors. Prior to joining AMAG, Mr. Heiden served as president and chief executive officer of GTC Biotherapeutics, Inc. since June 2010. Prior to joining GTC Biotherapeutics, Mr. Heiden was the president and chief executive officer and a member of the board of directors of Elixir Pharmaceuticals, Inc., a pharmaceutical company, from September 2004 until December 2008.
Prior to joining Elixir Pharmaceuticals, Mr. Heiden served as president and chief operating officer of Praecis Pharmaceuticals Incorporated (which was acquired by GlaxoSmithKline plc), from 2002 to 2004. From 1987 to 2002, Mr. Heiden progressed through various positions of increasing responsibility at Schering-Plough Corporation (now Merck & Co.), including managing a number of businesses in the United States, Europe and Canada. Mr. Heiden served on the board of directors of GTC Biotherapeutics, Inc., rVEO Biologics and LFB Biotechnologies S.A.S., a private French biotechnology company. Mr. Heiden holds an M.B.A. from Cornell University’s Johnson Graduate School of Management, a M.I.M. degree from the University of Louvain and a B.A. degree from the University of Florida.
Joel S. Marcus
Joel S. Marcus is the Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. (NYSE:ARE), an urban office REIT uniquely focused on collaborative life science and technology campuses in AAA innovation cluster locations. Mr. Marcus co-founded Alexandria in 1994 as a garage startup with $19 million in Series A capital and, as Chief Executive Officer from March 1997 to April 2018, has led its growth into an S&P 500 company with an approximately $18 billion total market capitalization and a total shareholder return of approximately 1,300% since the company’s IPO in 1997. Today, Alexandria, which celebrated its 20th anniversary as an NYSE listed REIT in May 2017, is the only publicly traded pure-play office/laboratory REIT.
Mr. Marcus has built Alexandria’s unique business model around four business verticals — real estate, venture investments, thought leadership, and corporate responsibility. With its core focus on real estate, Alexandria has a proven track record of developing Class A buildings on urban life science and technology campuses in AAA innovation cluster locations, including Greater Boston, San Francisco, New York City, San Diego, Seattle, Maryland, and Research Triangle Park. In 1996, Mr. Marcus founded the company’s venture capital arm, Alexandria Venture Investments, to provide strategic investment capital to innovative life science and technology entities developing breakthrough therapies and technologies. Mr. Marcus introduced the company’s thought leadership platform in 2011, when he co-founded the renowned Alexandria Summit®. The Alexandria Summit convenes a diverse group of visionary partners and key stakeholders — from the pharmaceutical, biotechnology, agribusiness, technology, medical, academic, venture capital, private equity, philanthropic, patient advocacy, and government communities — to address the most critical challenges in global healthcare, agriculture, and the environment. Focusing on sustainability and philanthropy, Alexandria’s corporate responsibility business vertical affirms the company’s commitment to making a positive impact on the world. Mr. Marcus is also personally engaged in numerous mission-critical philanthropic efforts, including through his service as Chair of the Navy SEAL Foundation’s 2017 New York City Benefit, which raised $12.8 million to help support the Naval Special Warfare community and their families.
In addition to Atara Biotherapeutics, Inc., Mr. Marcus was one of the original architects and co-founders of Accelerator Life Science Partners, for which he serves on the board of directors, and AgTech Accelerator Corporation, for which he serves as Chairman of the board. He also serves on the boards of Applied Therapeutics Inc., Boragen Inc., Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), MeiraGTx Limited, and Yumanity Therapeutics; Biotechnology Innovation Organization (BIO), the Foundation for the National Institutes of Health (FNIH), Friends of Cancer Research, MassBio, NewYorkBIO, and The Scripps Research Institute; the 9/11 Memorial & Museum, the Navy SEAL Foundation, the Partnership for New York City, and Robin Hood Foundation; as well as on Nareit’s 2018 Executive Board.
Prior to co-founding Alexandria, Mr. Marcus had an extensive legal career specializing in corporate finance and capital markets, venture capital, and mergers and acquisitions. During that time, he acquired an expertise in the biopharmaceutical industry and was one of the principal architects of the Kirin-Amgen EPO joint venture in 1984. He was also a practicing certified public accountant and tax manager with Arthur Young & Co., where he focused on the financing and taxation of REITs. He was named one of Real Estate Forum’s 2017 Best Bosses in commercial real estate and was previously a recipient of the EY Entrepreneur Of The Year Award (Los Angeles — Real Estate). Mr. Marcus earned his undergraduate and Juris Doctor degrees from the University of California, Los Angeles.
Beth Seidenberg, M.D.
Dr. Beth Seidenberg is a partner at Kleiner Perkins Caufield & Byers focused on life science investing. She works with entrepreneurs to develop companies with breakthrough technology for treating patients and improving health. Since joining KPCB in 2005, Beth has incubated five companies and also serves on the board of directors of 3-V Biosciences, Armo Biosciences, Auxogyn, Breathe Technologies, Epizyme, iPierian, FLX, Redbrick Health and TESARO.
Before joining KPCB, Beth was the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, Inc. Earlier in her career, she was a senior executive in research and development at Bristol-Myers Squibb Company and Merck, Inc. Under her leadership, 10 innovative products were developed and marketed globally and achieved more than 40 regulatory approvals. Beth received her B.S. degree from Barnard College and her M.D. from the University of Miami School of Medicine. She completed her post-graduate training at The Johns Hopkins University, George Washington University and the National Institutes of Health.